Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 12, 2026

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Aug 12, 2026

Diamond Hill Mid Cap Fund Q2 2026 Contributors And Detractors

Equity markets posted strong returns during the second quarter, with robust corporate earnings and a resilient domestic economy supporting investor sentiment. Key contributors were Humana, Regal Rexnord, and Illumina. Key detractors were Huntington Ingalls, Wix.com, and Zoetis.

Seeking Alpha • Aug 11, 2026

What Makes Illumina (ILMN) a New Strong Buy Stock

Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Aug 7, 2026

Here's Why Illumina (ILMN) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Aug 6, 2026

Illumina, Inc. (ILMN) Hits Fresh High: Is There Still Room to Run?

Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Aug 3, 2026

Illumina, Inc. (ILMN) Q2 2026 Earnings Call Transcript

Illumina, Inc. (ILMN) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 30, 2026

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 2026 results Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China ("ROW1 organic revenue growth") GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31 "Illumina delivered strong results during the second quarter.

PRNewsWire • Jul 30, 2026

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

Illumina (ILMN) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.19 per share a year ago.

Zacks Investment Research • Jul 30, 2026

Illumina (ILMN) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Jul 31, 2026